prostate cancer

Genetic predictors could improve PSA accuracyA recent study has found that genetic predictors of normal PSA levels in healthy men could be used to improve the accuracy of PSA-based prostate cancer screening.
Urology FDA approvals of 2016Urology-related FDA approvals from 2016 encompassed drugs and devices for prostate cancer, renal cell carcinoma, bladder cancer, stone disease, and more.
Salvage LND: Complete PSA response achievableSalvage lymph node dissection results in an immediate complete PSA response in about one-third of patients with rising PSA and nodal recurrence following local therapy for prostate cancer, according to German researchers.
When is a patient cured after prostatectomy?"Rather than making a blanket statement regarding continued follow-up, we need to consider the pathologic features commonly known to increase the risk of [prostate cancer] recurrence—concurrent medical problems, the patient’s age at recurrence, PSA doubling time, longevity in the family, etc," writes J. Brantley Thrasher, MD.
Biochemical recurrence risk high 10 years post-RPThe risk for biochemical recurrence of prostate cancer remains relatively high even 10 years after radical prostatectomy, but it does not appear to be influenced by a positive family history of prostate cancer or a family or personal history of other cancer, according to a study analyzing data from the prospective German Familial Prostate Cancer database.
Guideline adherence down for combination RT-ADTAdherence to guidelines for the use of combination radiation therapy and androgen deprivation therapy in the United States for the treatment of high-risk or locally advanced prostate cancer has decreased over time, according to data presented by Paolo Dell’Oglio, MD.
Post-RT proctitis less likely in ACE inhibitor usersHigh-grade proctitis after radical radiation therapy with neoadjuvant or adjuvant hormonal therapy is significantly less likely in patients taking angiotensin-converting-enzyme inhibitors.
Can a low-inflammation diet alter prostate health?
Major decline in prostate Bx rates follows PSA publications“It is clear that in order to reduce the morbidity of PSA screening and early detection of prostate cancer, more needs to be done,” writes Badar M. Mian, MD.
Studies reveal drop in PCa treatment, rise in metastatic diseaseFindings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.